October 24, 2017 - The parties filed a stipulation of voluntary dismissal with prejudice.
September 28, 2017 - The court granted defendants' motion to dismiss with leave to amend.

September 2, 2016 - Defendants filed a motion to dismiss.

July 8, 2016 - The lead plaintiff filed an amended complaint.

May 13, 2016 - Lead plaintiff and lead counsel were appointed.

September 22, 2015 - Lead plaintiff motions were filed.

July 24, 2015 - An investor in shares of XOMA Corp (NASDAQ: XOMA) filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by XOMA Corp in connection with certain allegedly false and misleading statements made between November 6, 2014 and July 21, 2015.

According to the complaint the plaintiff alleges on behalf of purchasers of XOMA Corp (NASDAQ: XOMA) common shares between November 6, 2014 and July 21, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 6, 2014 and July 21, 2015 defendants made allegedly false and/or misleading statements that Xoma Corp's EYEGUARD-B clinical trial would succeed and/or surpass expectations across the study's primary endpoint.

XOMA Corp reported that its annual Total Revenue declined from $35.45 million in 2013 to $18.87 million in 2014, while its respective Net Loss declined from $124.06 million to $38.30 million.

On July 22, 2015, XOMA Corp announced results From Phase 3 EYEGUARD(TM)-B Study. Xoma Corp said that a Phase III trial of its treatment (gevokizumab) for Behcet's disease in the eye missed the primary endpoint of time to first acute ocular exacerbation. The company announced that it will continue to work with its French partner, Servier, to conduct a thorough analysis of the data. Shares of XOMA Corp (NASDAQ: XOMA) declined from $4.45 per share on July 21, 2015, to $0.88 per share on July 22, 2015.